Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Robert on the Trametinib METRIC Trial Results

June 4th 2012

Dr. Caroline Robert, from the Institute Gustave Roussy in Paris, France, Discusses the MEK Inhibitor, Trametinib, METRIC Trial Results.

CDX-011 Shows Promise in GPNMB-Positive Triple-Negative Breast Cancer

May 23rd 2012

CDX-011, a targeted therapy designed to treat patients with advanced breast cancer, appears to increase PFS in TNBC patients who have received multiple prior lines of therapy and express GPNMB.

Combining Two Targeted Therapies Stalls Disease Progression in Melanoma Patients With BRAF Mutations

May 16th 2012

A combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has shown promising activity in patients with advanced melanoma.

Dr. Chapman on BRAF/MEK Combination for Melanoma

May 16th 2012

Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma

Dr. Goy on Crizotinib for Pediatric Patients With ALCL

May 16th 2012

Dr. Andre Goy, from John Theurer Cancer Center, on Crizotinib for Pediatric Patients With ALCL

Crizotinib Active in ALK-Positive Pediatric Cancers

May 16th 2012

Targeting the ALK gene with the oral agent crizotinib slowed or eliminated signs of tumor growth in pediatric patients with aggressive forms of neuroblastoma, ALCL, and IMTs.

Dr. Spector Discusses Breast Cancer Heterogeneity

May 14th 2012

Dr. Neil Spector, from Duke Cancer Institute, Explains Breast Cancer Heterogeneity

Dr. Ellis on Heterogeneity Impacting Biomarker Efficacy

May 9th 2012

Dr. Matthew Ellis, from Siteman Cancer Center, on Heterogeneity Impacting Biomarker Efficacy

Moffitt Cancer Center: Cutting-Edge, Total Cancer Care

May 9th 2012

Located in Tampa, Florida, Moffitt Cancer Center enjoys a reputation as one of the world's most sophisticated cancer centers.

Identifying Appropriate Patients for HER2-Targeted Therapies

May 6th 2012

Standards for identifying appropriate populations for treatment with HER2-targeted therapies are evolving.

Battling the Odds in RCC: Interview With Brian Rini, MD

May 5th 2012

An interview with Brian Rini, MD, whose research has focused on RCC, prostate, and other genitourinary cancers, as well as on antiangiogenic therapy and immunotherapy.

Oncology Nurses Need to Enhance Their Genetics and Genomics Competency

May 4th 2012

A pilot study has demonstrated a lag in the integration of genetics and genomics into nursing practice, which is an increasingly required professional skill for oncology nurses.

Managing Dermatologic Toxicities Associated With Targeted Therapies

May 1st 2012

Many targeted therapies are associated with dermatologic side effects; the monitoring and treating of these side effects should be done on an individual patient basis.

Dr. Spector on the Importance of Tumor Microenvironments

April 30th 2012

Dr. Neil Spector, from Duke Cancer Institute, Emphasizes the Importance of Studying Tumor Microenvironments

Landmark Study Redefines Breast Cancer Into 10 Subtypes

April 25th 2012

Researchers have determined that breast cancer can be classified into 10 different subtypes instead of four subtypes as previously thought.

Five Questions for Leonard M. Neckers, PhD

April 24th 2012

Leonard M. Neckers, PhD, has been studying the role of the molecular chaperone Hsp90 in signal transduction and the translational development of Hsp90-targeted anticancer agents for two decades.

Targeting Hsp90: Researchers Aim to Thwart Chaperones of the 'Guardian of the Proteome'

April 24th 2012

Hsp90 may be referred to as the 'guardian of the proteome,' since it regulates the correct structure and function of many of the important proteins encoded by our DNA.

Dr. Perez on the Mayo Clinic Breast Cancer Genomic Study

April 23rd 2012

Dr. Edith Perez, from the Mayo Clinic, Describes the Breast Cancer Translational Genomics Program

Breakthroughs in Targeted Therapies Not Applicable if Not Cost-Effective

April 20th 2012

Before the oncology treatment paradigm can move from a one-size-fits-all model to true personalized medicine, the medical establishment must find a cost-effective way to identify biomarkers.

Going Beyond the Label: Targeted Therapies Present New Questions in Clinical Use

April 18th 2012

The long-sought aim of treating malignant disease by targeting particular molecular abnormalities is becoming a reality in an increasing number of clinical settings.